Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Iconovo

1.14 SEK

+3.64 %

Less than 1K followers

ICO

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
+3.64 %
-3.39 %
0.00 %
-28.97 %
-44.12 %
-71.39 %
-97.17 %
-97.62 %
-96.50 %

Iconovo operates in the medical technology sector. The company develops inhalers for medical use. The company's products are used in the treatment of asthma and coal, where the inhalers consist of powder-based medicine. The products are licensed and sold under various brands. In addition to product development, there is expertise in pharmaceutical formulation. The company was founded in 2013 and has its headquarters in Lund.

Read more
Market cap
109.64M SEK
Turnover
80.73K SEK
Revenue
1.11M
EBIT %
-3,883.78 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
24/4
2026

Interim report Q1'26

28/5
2026

General meeting '26

20/8
2026

Interim report Q2'26

All
Press releases
3rd party
ShowingAll content types
Press releaseyesterday

DNB Carnegie Access: Iconovo: Still needs proof – Q4 review

Iconovo
Press release2/13/2026, 1:45 PM

DNB Carnegie Access: Iconovo - Q4 2025 - Intervju

Iconovo
Regulatory press release2/13/2026, 7:30 AM

The subscription period in Iconovo's rights issue begins today

Iconovo

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release2/13/2026, 7:30 AM

Idag inleds teckningsperioden i Iconovos företrädesemission av aktier

Iconovo
Regulatory press release2/12/2026, 1:30 PM

Iconovo offentliggör informationsdokument avseende företrädesemission av aktier

Iconovo
Regulatory press release2/12/2026, 1:30 PM

Iconovo publishes information document regarding rights issue of shares

Iconovo
Regulatory press release2/12/2026, 7:30 AM

Bokslutskommuniké 1 januari - 31 december 2025

Iconovo
Regulatory press release2/12/2026, 7:30 AM

Year-end report 1 January - 31 December 2025

Iconovo
Press release1/15/2026, 9:15 AM

Iconovo har initierat genomförbarhetsstudie i samarbete med multinationellt bolag för ICOone® Nasal

Iconovo
Press release1/15/2026, 9:15 AM

Iconovo has initiated a new feasibility study for ICOone® Nasal in collaboration with multinational company

Iconovo
Press release1/13/2026, 12:40 PM

EPO avser att godkänna patentansökan för ICOpre®

Iconovo
Press release1/13/2026, 12:40 PM

EPO declares intention to approve ICOpre® patent application

Iconovo
Regulatory press release12/22/2025, 9:00 AM

Valberedning utsedd Iconovo

Iconovo
Regulatory press release12/22/2025, 9:00 AM

Nomination Committee appointed at Iconovo AB

Iconovo
Regulatory press release12/16/2025, 11:45 AM

Iconovo meddelar att villkoren för tilldelning av aktier i riktad emission är uppfyllda

Iconovo
Regulatory press release12/16/2025, 11:45 AM

Iconovo announces that the terms and conditions for allotment of shares in directed issue are met

Iconovo
Regulatory press release12/15/2025, 9:30 AM

Kommuniké från extra bolagsstämma i Iconovo AB den 15 december 2025

Iconovo
Press release11/26/2025, 11:47 AM

DNB Carnegie Access: Iconovo: Raises capital

Iconovo
Regulatory press release11/25/2025, 8:15 PM

Kallelse till extra bolagsstämma i Iconovo AB

Iconovo
Regulatory press release11/25/2025, 8:05 PM

Iconovo genomför en riktad emission av aktier om cirka 25 MSEK och en företrädesemission av aktier om cirka 24,6 MSEK vilken omfattas till 100% av teckningsförbindelser och garantiåtaganden

Iconovo
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.